“Rare” can be misleading when it comes to rare disease. The term can evoke a handful of cases scattered around the world, or conditions so unusual that they barely register as a public health concern. The numbers tell a different story. According to Rare Diseases International, between 6,000 and 8,000 known rare diseases affect an … Continued
Traditional market-access frameworks may not fully reflect the economic realities of LMICs, where affordability and out-of-pocket costs can create significant barriers to treatment. Traditional market-access frameworks may not fully reflect the economic realities of LMICs, where affordability and out-of-pocket costs can create significant barriers to treatment. Axios highlighted how affordability segmentation tcan be used effectively … Continued
Earlier this month, Dr. Joseph Saba joined the “Priorities and Challenges in Polish and European Drug Policy 2025” Conference to share insights on advancing access to medicines in a world shaped by growing discord and policy uncertainty. “Me-first” trade policies could unravel decades of progress on medicine access. As geopolitical and trade pressures reshape medicine … Continued
Healthcare transformation can create new opportunities to improve how patients access care and treatment, but access strategies need to evolve alongside changes in policy, infrastructure and care delivery. Healthcare transformation can create new opportunities to improve how patients access care and treatment, but access strategies need to evolve alongside changes in policy, infrastructure and care … Continued
What Happens When Financial Support Isn’t Enough to Start Treatment? Financial assistance is often viewed as the final step in making treatment accessible. Once the cost barrier has been addressed, it can be tempting to assume the patient will simply begin treatment. In practice, there can be another gap between being approved for support and … Continued
Medical innovation only creates value when patients can access and benefit from it. Affordability, treatment initiation and ongoing support can all influence whether patients successfully receive their treatment. Medical innovation only creates value when patients can access and benefit from it. Affordability, treatment initiation and ongoing support can all influence whether patients successfully receive their … Continued
Axios International signed an MOU with Malaysia’s Ministry of Health and the National Cancer Society Malaysia in support of the National Lung Health Initiative, strengthening collaboration around national health priorities and patient access. Partnerships between governments, healthcare organizations and other stakeholders can bring together expertise and resources to address complex healthcare challenges. The collaboration connects … Continued
Patients can face healthcare access barriers even when they have the means to pay for treatment over time. In this discussion, Axios leaders explore how cash flow challenges can delay treatment and introduce On-Time Access (OTA), a new model designed to help eligible patients access treatment when they need it. The conversation also examines innovative … Continued
Why One Approach to Affordability Doesn’t Work The number of people living with chronic and serious diseases continues to rise worldwide. At the same time, advances in science and technology are making more innovative treatments available to patients. But making a treatment available does not necessarily mean a patient can access it, or remain on … Continued